Clinical Trial

Real-World Effectiveness of Benralizumab in Allergic Bronchopulmonary Aspergillosis

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated April 21, 2026 (before its estimated July 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
An open-label study will evaluate effects of Benralizumab in the treatment of severe asthma in patients with allergic bronchopulmonary aspergillosis
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-04-08.
Trial Details
NCT Number NCT07530770
Lead Sponsor Qianfoshan Hospital
Conditions Allergic Bronchopulmonary Aspergillosis, Severe Asthma, ABPA
Enrollment 20 participants
Start Date 2025-09-01
Primary Completion 2026-07-31 (estimated)
Study Completion 2026-12-01 (estimated)
Updated on ClinicalTrials.gov 2026-04-21